Test Description

Direct oral anticoagulants (DOAC) such as Rivaroxaban (Xarelto®) and Apixaban (Eliquis®) are highly utilized for anticoagulation in individuals with non-valvular atrial fibrillation, a recent thrombotic event or those with a substantial risk for recurrent thromboses. Some of these patients often are in need of laboratory testing for a Lupus Anticoagulant (LAC). Direct oral anticoagulant medications can interfere with LAC testing causing false-positive or false-negative test results.  We are now offering Lupus Anticoagulant Testing after the DOAC* removal process from plasma. We have validated a methodology to perform LAC testing that can now offer accurate results for the activated partial thromboplastin time (APTT), dilute Russell’s viper venom time (dRVVT), and Hexagonal Phase Phospholipid Neutralization Assays. With this methodology, clinicians will no longer have to consider removing a patient from DOAC* use to perform LAC testing. This provides the unique opportunity to maintain patient safety by continuing necessary DOAC use while performing LAC testing.

 *The DOAC Remove process has been validated for Rivaroxaban and Apixaban only at this time